Kaufman Rossin Wealth LLC Invests $320,000 in Johnson & Johnson $JNJ

Key Points

• Kaufman Rossin Wealth LLC invested $320,000 in Johnson & Johnson, acquiring 1,927 shares during the first quarter.
• Several analysts have issued mixed ratings for Johnson & Johnson, with some lowering their target price from $169 to $153, but the consensus rating remains a "Moderate Buy."
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, representing a 2.9% dividend yield and a payout ratio of 55.61%.

Kaufman Rossin Wealth LLC acquired a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,927 shares of the company's stock, valued at approximately $320,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Elios Financial Group Inc. raised its stake in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC grew its holdings in shares of Johnson & Johnson by 4.4% during the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after buying an additional 67 shares in the last quarter. MBA Advisors LLC increased its stake in shares of Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after purchasing an additional 68 shares during the period. Sovereign Financial Group Inc. grew its stake in Johnson & Johnson by 1.8% during the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after buying an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc raised its position in shares of Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after buying an additional 69 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Finally, UBS Group lifted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $178.5890 on Thursday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $180.61. The business has a fifty day moving average price of $162.59 and a 200-day moving average price of $158.87. The company has a market capitalization of $430.10 billion, a PE ratio of 19.10, a PEG ratio of 2.26 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the previous year, the company earned $2.82 earnings per share. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson's payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.